| Primary |
| Psoriasis |
70.1% |
| Product Used For Unknown Indication |
18.8% |
| Renal Transplant |
3.5% |
| Drug Use For Unknown Indication |
2.2% |
| Graft Versus Host Disease |
1.4% |
| Hypertension |
0.8% |
| Angina Pectoris |
0.4% |
| Drug Exposure During Pregnancy |
0.4% |
| Vitiligo |
0.4% |
| Angioimmunoblastic T-cell Lymphoma |
0.3% |
| Dermatitis Atopic |
0.3% |
| Guttate Psoriasis |
0.3% |
| Anxiety |
0.2% |
| Chronic Obstructive Pulmonary Disease |
0.2% |
| Hyperlipidaemia |
0.2% |
| Medical Diet |
0.2% |
| Urinary Tract Infection |
0.2% |
| Attention Deficit/hyperactivity Disorder |
0.1% |
| Blood Cholesterol |
0.1% |
| Cardiac Disorder |
0.1% |
|
| Death |
19.8% |
| Diabetes Mellitus |
11.6% |
| Surgery |
7.0% |
| Myocardial Infarction |
6.2% |
| Urinary Tract Infection |
5.8% |
| Kidney Transplant Rejection |
5.0% |
| Diverticulitis |
4.5% |
| White Blood Cell Count Increased |
4.1% |
| Cellulitis |
3.7% |
| Staphylococcal Infection |
3.7% |
| Weight Decreased |
3.7% |
| Cerebrovascular Accident |
3.3% |
| Hospitalisation |
3.3% |
| No Therapeutic Response |
2.9% |
| Transient Ischaemic Attack |
2.9% |
| Appendicitis |
2.5% |
| Nephrolithiasis |
2.5% |
| Renal Impairment |
2.5% |
| Squamous Cell Carcinoma |
2.5% |
| Type 2 Diabetes Mellitus |
2.5% |
|
| Secondary |
| Product Used For Unknown Indication |
72.9% |
| Renal Transplant |
12.3% |
| Psoriasis |
7.0% |
| Anxiety |
1.1% |
| Graft Versus Host Disease |
1.1% |
| Chronic Obstructive Pulmonary Disease |
0.7% |
| Gout |
0.7% |
| Hyperlipidaemia |
0.7% |
| Medical Diet |
0.7% |
| Attention Deficit/hyperactivity Disorder |
0.4% |
| Diabetes Mellitus |
0.4% |
| Headache |
0.4% |
| Muscle Spasms |
0.4% |
| Neutropenia |
0.4% |
| Platelet Count Decreased |
0.4% |
| Prophylaxis Against Graft Versus Host Disease |
0.4% |
| Renal Failure Acute |
0.4% |
|
| Kidney Transplant Rejection |
31.9% |
| Antibody Test Positive |
12.8% |
| Bone Pain |
4.3% |
| Gastritis |
4.3% |
| Leukaemia |
4.3% |
| Neutropenia |
4.3% |
| Neutrophil Count Decreased |
4.3% |
| Off Label Use |
4.3% |
| Respiratory Failure |
4.3% |
| Transient Ischaemic Attack |
4.3% |
| Cerebrovascular Accident |
2.1% |
| Chronic Obstructive Pulmonary Disease |
2.1% |
| Deep Vein Thrombosis |
2.1% |
| Foetal Exposure During Pregnancy |
2.1% |
| Gastroenteritis |
2.1% |
| Hepatitis A |
2.1% |
| Hypoglycaemia |
2.1% |
| T-lymphocyte Count Decreased |
2.1% |
| Treatment Failure |
2.1% |
| Unevaluable Event |
2.1% |
|
| Concomitant |
| Psoriasis |
45.7% |
| Hypertension |
14.3% |
| Diabetes Mellitus |
12.9% |
| Product Used For Unknown Indication |
10.0% |
| Multiple Sclerosis |
2.9% |
| Prophylaxis |
2.9% |
| Schizoaffective Disorder |
2.9% |
| Schizophrenia |
2.9% |
| Chronic Sinusitis |
1.4% |
| Contraception |
1.4% |
| Dermatitis Atopic |
1.4% |
| Psoriatic Arthropathy |
1.4% |
|
| Presyncope |
25.0% |
| Death |
12.5% |
| Loss Of Consciousness |
12.5% |
| Diarrhoea |
6.3% |
| Drug Ineffective |
6.3% |
| Injection Site Pain |
6.3% |
| Platelet Count Decreased |
6.3% |
| Red Blood Cell Count Decreased |
6.3% |
| Skin Fissures |
6.3% |
| Transient Ischaemic Attack |
6.3% |
| Type 2 Diabetes Mellitus |
6.3% |
|
